Pfizer and BioNTech Announce 'Highly Effective' Vaccine
The companies said that early analysis of the results showed that patients who received two injections of the vaccine three weeks apart experienced more than 90% fewer cases of symptomatic COVID-19 than did those who received a placebo.
First, the good news: if the current results hold, they're much better than expected for any COVID-19 vaccine. To date, researchers have been warning that a vaccine might only be 60-70% effective.
Pfizer's news must be taken with a massive grain of salt. For one thing, the Phase 3 safety trial is ongoing, and additional data could affect results. It's also not yet known if the vaccine prevents people from carrying the COVID-19 virus and spreading it as asymptomatic carriers.
Read more about the vaccine here, then join the conversation:
Do you plan on taking a COVID-19 vaccine?
|